ng/mL was determined as the cfDNA cut-off value for comparison. The sensitivity and specificity of the dichotomized cfDNA (≤ 50 vs. > 50 ng/mL) were 58.8% and 91.7%, respectively. (B) Stages I-II vs. stages III-IV; the AUC was 0.727 (p < 0.002; 95% CI: 0.621-0.834), and 50 ng/mL was determined as the cfDNA cut-off value for comparison. The sensitivity and specificity of the dichotomized cfDNA (≤ 50 vs. > 50 ng/mL) were 60.4% and 88.9%, respectively. (C) Stage I-III vs. stage IV; the AUC was 0.658 (p < 0.002; 95% CI: 0.568-0.748), and 50 ng/mL was determined as the cfDNA cut-off value for comparison. The sensitivity and specificity of the dichotomized cfDNA (≤ 50 vs. > 50 ng/mL) were 62.0% and 67.5%, respectively. AUC, area under the curve; ROC, receiver operating characteristic; cfDNA, cell-free DNA; NSCLC, non-small-cell lung cancer; CI, confidence interval. 
